Abstract
Adverse effects related to clozapine were assessed within a post-marketing drug surveillance program, the AMÜP study, in two university psychiatric departments. In a randomly selected sample of patients (intensive drug monitoring) ADRs of any type were observed in 76% of clozapine-treated inpatients. Sedation, hypersalivation, increase in transaminases, and EEG changes were most frequently observed, but only rarely required changes in therapy. In 8.1% of 959 patients exposed to clozapine in the total inpatient population of the participating hospitals ADR led to withdrawal of clozapine; in 3.9% reactions judged as severe and potentially life-threatening occurred. Among these latter toxic delirium prevailed. In addition, four cases of severe cardiovascular and respiratory dysregulation were observed with the combination of clozapine and benzodiazepines. These cases and one case of sudden death under clozapine and haloperidol treatment are presented in some detail. The results obtained for clozapine are compared to data from this drug surveillance program for other neuroleptics.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Grohmann R, Hippius H, Müller-Oerlinghausen B, Rüther E, Scherer J, Schmidt LG, Strauß A, Wolf B (1984) Assessment of adverse drug reactions in psychiatric hospitals. Eur J Clin Pharmacol 26:727–734
Grohmann R, Koch R, Rüther E, Schmidt LG (1988) Nebenwirkungen von Perazin im Vergleich zu anderen Neuroleptika. In: Helmchen H, Hippius H, Tölle R (eds) Therapie mit Neuroleptika-Perazin. Thieme, New York, pp 74–82
Grohmann R, Schmidt LG, Spieß-Kiefer C, Rüther E (1989) Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMÜP program. Psychopharmacology [Suppl] 99:S109-S112
Hurwitz N, Wade OL (1969) Intensive hospital monitoring of adverse reactions to drugs. Br Med J 1:531–536
Idäänpään-Heikkilä J, Alhava, Olkinuora M, Palva IP (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193–198
Müller-Spahn F, Grohmann R, Rüther E (1988) Vor- und Nachteile einer Kombinationstherapie mit Perazin. In: Helmchen H, Hippius H, Tölle R (eds) Therapie mit Neuroleptika-Perazin. Thieme, New York, pp 136–144
Rüther E, Benkert O, Eckmann F, Eckmann I, Grohmann R, Helmchen H, Hippius H, Müller-Oerlinghausen B, Poser W, Schmidt LG, Stille G, Strauß A, Überla K (1980) Drug Monitoring in psychiatrischen Kliniken. Bericht der Arbeitsgruppe für Medikamenten-Überwachung in der Psychiatrie. Arzneimittelforschung/Drug Res 30:1181–1183
Schmidt LG, Grohmann R, Helmchen H, Langscheid-Schmidt K, Müller-Oerlinghausen B, Poser W, Rüther E, Scherer J, Strauß A, Wolf B (1984) Adverse drug reactions. An epidemiological study at psychiatric hospitals. Acta Psychiatr Scand 70:77–89
Schmidt LG, Grohmann R, Strauß A, Spieß-Kiefer C, Lindmeier D, Müller-Oerlinghausen B (1987) Epidemiology of toxic delirium due to psychotropic drugs in psychiatric hospitals. Comp Psychiatry 28:242–249
Seidl LG, Thornton GF, Cluff LE (1965) Epidemiological studies of adverse drug reactions. Am J Public Health 55:1170–1175
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grohmann, R., Rüther, E., Sassim, N. et al. Adverse effects of clozapine. Psychopharmacology 99 (Suppl 1), S101–S104 (1989). https://doi.org/10.1007/BF00442571
Issue Date:
DOI: https://doi.org/10.1007/BF00442571